Summary
GlobalData, the industry analysis specialist's new report, "Venous Thromboembolism-Drug Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global venous thromboembolism market. The report identifies the key trends shaping and driving the global venous thromboembolism market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global venous thromboembolism sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope
The scope of the report includes:
-Annualized global venous thromboembolism market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
-Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
-Analysis of the current and future market competition in the global venous thromboembolism market. Key players covered include Bristol-Meyers Squibb Company, Pfizer, Inc., Sanofi-Aventis, Daiichi Sankyo Co.Ltd., Astellas Pharmas, Inc, Bayer Healthcare, and Johnson & Johnson.
-Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with venous thromboembolism.

Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global venous thromboembolism market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global venous thromboembolism market in future.
-Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global venous thromboembolism market landscape? -Identify, understand and capitalize.

Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Venous Thromboembolism Market: Market Characterization 6
2.1 Overview 6
2.2 Venous Thromboembolism Market Size 6
2.3 Venous Thromboembolism Market Forecast and CAGR 6
2.4 Drivers and Barriers for the Venous Thromboembolism Market 7
2.4.1 Drivers for the Venous Thromboembolism Market 8
2.4.2 Barriers for the Venous Thromboembolism Market 8
2.5 Opportunity and Unmet Need 8
2.6 Key Takeaway 9
3 Venous Thromboembolism Market: Competitive Assessment 10
3.1 Overview 10
3.2 Strategic Competitor Assessment 10
3.3 Product Profiles of the Major Marketed Products in Venous Thromboembolism Market-Heparin Class 11
3.3.1 Enoxaparin (Lovenox or Clexane) 11
3.3.2 Nadroparin (Fraxiparine) 12
3.3.3 Dalteparin (Fragmin) 13
3.3.4 Tinzaparin (Innohep) 14
3.4 Product Profiles of the Major Marketed Products in Venous Thromboembolism Market-Vitamin K Antagonist Class 15
3.4.1 Warfarin 15
3.5 Product Profiles of the Major Marketed Products in Venous Thromboembolism Market-Direct Thrombin Inhibitor Class 16
3.5.1 Lepirudin (Refludan) 16
3.5.2 Argatroban 17
3.5.3 Dabigatran Etexilate (Pradaxa) 17
3.5.4 Antithrombin Recombinant (ATryn) 18
3.6 Product Profiles of the Major Marketed Products in Venous Thromboembolism Market-Synthetic Pentasaccharide Class 18
3.6.1 Fondaparinux (Arixtra) 18
3.7 Product Profiles of the Major Marketed Products in Venous Thromboembolism Market-Thrombolytics Class 19
3.7.1 Alteplase 19
3.8 Key Takeaway 22
4 Venous Thromboembolism Market: Pipeline Assessment 23
4.1 Overview 23
4.2 Strategic Pipeline Assessment 23
4.2.1 Technology Trends Analytic Framework 23
4.3 Venous Thromboembolism Therapeutics-Promising Drugs under Clinical Development 25
4.4 Molecule Profile for Promising Drugs under Clinical Development 25
4.4.1 Xarelto 25
4.4.2 Apixaban 27
4.4.3 DU-176b (Edoxaban) 28
4.4.4 YM150 28
4.4.5 AVE 5026 29
4.5 Venous Thromboembolism Therapeutics Market-Clinical Pipeline by Mechanism of Action 29
4.6 Venous Thromboembolism Pipeline-Pipeline by Clinical Phases of Development 30
4.6.1 Venous Thromboembolism Therapeutics-Regulatory Filing and Phase III Clinical Pipeline   31
4.6.2 Venous Thromboembolism Therapeutics-Phase II Clinical Pipeline 32
4.6.3 Venous Thromboembolism Therapeutics-Regulatory and Phase I Clinical Pipeline 33
4.6.4 Venous Thromboembolism Therapeutics-Preclinical and Discovery Clinical Pipeline 33
4.6.5 Discontinued/Suspended Drugs for Venous Thromboembolism 34
4.7 Key Takeaway 34
5 Venous Thromboembolism Market: Implications for Future Market Competition 35
6 Venous Thromboembolism Market: Future Players in the Venous Thromboembolism Market 36
6.1 Introduction 36
6.2 Bristol-Myers Squibb Company 36
6.2.1 Company Overview 36
6.2.2 Business Description 37
6.2.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 37
6.2.4 Venous Thromboembolism Product Portfolio 38
6.3 Pfizer, Inc. 39
6.3.1 Company Overview 39
6.3.2 Business Description 39
6.3.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 40
6.3.4 Venous Thromboembolism Product Portfolio 40
6.4 Sanofi-Aventis 40
6.4.1 Company Overview 40
6.4.2 Business Description 41
6.4.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 42
6.4.4 Venous Thromboembolism Product Portfolio 43
6.5 Daiichi Sankyo Co.Ltd 43
6.5.1 Company Overview 43
6.5.2 Business Description 44
6.5.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 45
6.5.4 Venous Thromboembolism Product Portfolio 45
6.6 Astellas Pharma, Inc. 45
6.6.1 Company Overview 45
6.6.2 Business Description 46
6.6.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 47
6.6.4 Venous Thromboembolism Product Portfolio 47
6.7 Bayer Healthcare 48
6.7.1 Company Overview 48
6.7.2 Business Description 48
6.7.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 48
6.7.4 Venous Thromboembolism Product Portfolio 49
6.8 Johnson & Johnson 50
6.8.1 Company Overview 50
6.8.2 Business Description 50
6.8.3 Cardiovascular and Thrombosis Pipeline Product Portfolio 51
6.8.4 Venous Thromboembolism Product Portfolio 51
7 Venous Thromboembolism Market: Appendix 52
7.1 Market Definition 52
7.2 Abbreviations 52
7.3 Research Methodology 53
7.3.1 Coverage 53
7.3.2 Secondary Research 54
7.3.3 Forecasting 54
7.3.4 Primary Research 57
7.3.5 Expert Panels 57
7.4 Contact Us 57
7.5 Disclaimer 57
7.6 Sources 58

List of Tables
1.1 List of Tables
Table 1:  Global Venous Thromboembolism Market Forecast ($m), 2001-2009 7
Table 2:  Global Venous Thromboembolism Market Forecast ($m), 2009-2016 7
Table 3:  Major Marketed Products Comparison in the Venous Thromboembolism Market, 2010 21
Table 4:  Venous Thromboembolism Therapeutics-Most Promising Drugs under Clinical Development, 2010 25
Table 5:  Venous Thromboembolism Therapeutics-Regulatory Filing and Phase III Clinical Pipeline, 2010 31
Table 6:  Venous Thromboembolism Therapeutics-Phase II Clinical Pipeline, 2010 32
Table 7:  Venous Thromboembolism Therapeutics-Phase I Clinical Pipeline, 2010 33
Table 8:  Venous Thromboembolism Therapeutics-Preclinical and Discovery Pipeline, 2010 33
Table 9:  List of Discontinued/Suspended Drugs for Venous Thromboembolism, 2010 34
Table 10:  Bristol-Myers Squibb Company-Cardiovascular and Thrombosis Pipeline, 2010 37
Table 11:  Pfizer Inc.-Cardiovascular and Thrombosis Pipeline, 2010 40
Table 12:  Sanofi-Aventis-Cardiovascular and Thrombosis Pipeline, 2010 42
Table 13:  Daiichi Sankyo Co. Ltd-Cardiovascular and Thrombosis Pipeline, 2010 45
Table 14:  Astellas Pharma Inc.-Cardiovascular and Thrombosis Pipeline, 2010 47
Table 15:  Bayer HealthCare-Cardiovascular and Thrombosis Pipeline, 2010 48
Table 16:  Johnson & Johnson-Cardiovascular and Thrombosis Pipeline, 2010 51

List of Figures
1.2 List of Figures
Figure 1:  Global Venous Thromboembolism Market Forecast ($m), 2001-2009 6
Figure 2:  Global Venous Thromboembolism Market Forecast ($m), 2009-2016 7
Figure 3:  Opportunity and Unmet Need in the Venous Thromboembolism Market, 2010 9
Figure 4:  Strategic Competitor Assessment of the Marketed Products for Venous Thromboembolism, 2010 11
Figure 5:  Technology Trends Analytic Framework of the Venous Thromboembolism Pipeline, 2010 24
Figure 6:  Technology Trends Analytic Framework of the Venous Thromboembolism Pipeline-Description, 2010 24
Figure 7:  Venous Thromboembolism Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2010 30
Figure 8:  Venous Thromboembolism Pipeline by Phase of Clinical Development, 2010 30
Figure 9:  Implications for Future Market Competition in the Venous Thromboembolism Market, 2010 35
Figure 10:  Venous Thromboembolism Therapeutics Market-Clinical Pipeline by Company, 2010 36
Figure 11:  GlobalData Methodology 53
Figure 12:  GlobalData Market Forecasting Model 56